20 results on '"Lufkin, Bradley"'
Search Results
2. Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy
3. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19- Related Thromboembolic Events Among Medicare Enrollees Aged [greater than or equal to] 65 Years and Those with End Stage Renal Disease--United States, September 2022-March 2023
4. 1173. Risk of Pneumococcal Disease and Rate of Pneumococcal Vaccination Among Medicare Beneficiaries Aged 65 Years and Older Residing in Long-Term Care Facilities — United States, September 1, 2014 – December 31, 2019
5. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing COVID-19-Related Thromboembolic Events Among Medicare Enrollees Aged ≥65 Years and Those with End Stage Renal Disease -- United States, September 2022-March 2023.
6. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019–2020
7. Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older
8. Disparities in erythropoiesis-stimulating agent use after changes in medicare reimbursement and implementation of a risk evaluation and mitigation strategy
9. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in the United States, 2019–2020
10. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries
11. Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA 's risk evaluation and mitigation strategy lifecycle
12. Recombinant Zoster Vaccine (Shingrix): Real-World Effectiveness in the First 2 Years Post-Licensure
13. Surveillance of COVID-19 Vaccine Safety Among Elderly Persons Aged 65 Years and Older
14. Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018–2019 Season
15. Trends in Erythropoiesis‐stimulating agent use and blood transfusions for chemotherapy‐induced anemia throughout FDA's risk evaluation and mitigation strategy lifecycle.
16. Surveillance for Guillain-Barré syndrome after 2015–2016 and 2016–2017 influenza vaccination of Medicare beneficiaries
17. Surveillance for Guillain-Barré syndrome after influenza vaccination among U.S. Medicare beneficiaries during the 2017–2018 season
18. Guillain-Barré Syndrome After High-Dose Influenza Vaccine Administration in the United States, 2018-2019 Season.
19. Interactive Graphics Plotting System (IGPS)
20. Interactive Graphics Plotting System (IGPS).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.